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Overview
The sixth TIM lecture of 2012 was presented by Louis 
Lamontagne, President and CEO of LTL Global Innova-
tions and Management. Lamontagne shared his experi-
ences  as  a  seasoned  entrepreneur  in  the  pharma- 
ceutical industry while reflecting on the "born global" 
concept, which refers to businesses that aim to address 
a global market from day one (Tanev, 2012; timreview.ca/
article/532). The event was held at Carleton University in 
Ottawa, Canada, on August 9th, 2012. 
The TIM Lecture Series is hosted by the Technology In-
novation Management program (TIM;  carleton.ca/tim) at 
Carleton  University.  The  lectures  provide  a  forum  to 
promote the transfer of knowledge from university re-
search  to  technology  company  executives  and  entre-
preneurs  as  well  as  research  and  development 
personnel. Readers are encouraged to share related in-
sights  or  provide  feedback  on  the  presentation  or  the 
TIM Lecture Series, including recommendations of fu-
ture speakers.
This  report  summarizes  the  presentation  and  its  key 
messages,  including  the  lessons  learned  by  audience 
members. 
Summary
Louis Lamontagne began the lecture by describing the 
various  definitions  that  exist  for  the  born-global  ap-
proach  to  internationalization.  The  born-global  ap-
proach is attracting increasing attention because of the 
potential advantages this approach offers over conven-
tional staged-internationalization approaches. 
Lamontagne  explained  that,  in  the  more  traditional, 
“step” model of internationalization, companies first es-
tablish  themselves  in  a  domestic  market,  where  they 
gain  an  understanding  of  the  market  and  (hopefully) 
demonstrate solid growth. Expansion to adjacent coun-
tries is slow as the companies gain familiarity and un-
derstanding  of  foreign  markets  before  venturing 
overseas.  In  contrast,  born-global  companies  interna-
tionalize at or near their founding.
The  born-global  approach  is  potentially  "game  chan-
ging"  and  disruptive  because  it  challenges  traditional 
views  of  business  internationalization.  That  said,  La-
montagne  cautions  that  the  existence  of  competing 
definitions  make  it  difficult  to  assess  the  born-global 
approach and compare studies. 
Lamontagne  distilled  the  most  commonly  recognized 
characteristics  of  born-global  companies  and  the 
strategies  they  employ  to  gain  competitive  advantage. 
Finally, he shared a pharmaceutical perspective on the 
born-global  concept  based  on  his  own  experiences  as 
an international entrepreneur. 
Although  the  born-global  concept  provided  the  back-
drop  for  the  lecture,  Lamontagne  pointed  out  that  he 
was not purporting himself to be an expert in the area. 
Rather, he wished to share his reflections on his own ca-
reer and experience to shed light on the born-global ap-
proach and stimulate discussion and a healthy debate.
Born Global by Design?
Among the multiple definitions of born-global compan-
ies, a key distinction is whether or not the approach is 
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intentional or is simply a by-product of a company's cir-
cumstance. Some definitions (e.g., Tanev, 2012: timreview
.ca/article/532;  Bailetti,  2012:  tinyurl.com/8aqppfc),  require 
the company to take deliberate action to compete glob-
ally  from  inception.  Nonetheless,  Lamontagne  argued 
that  whether  a  company  is  global  by  design  or  emer-
gence, the "new global marketplace" has made condi-
tions  more  favourable  for  early  internationalization. 
These favourable conditions include modern informa-
tion  and  communication  technologies,  cost-effective 
global transportation systems, just-in-time manufactur-
ing, global networks and alliances, and e-commerce.
Distinctive Characteristics of Born Globals
Born-global companies seem to share the following dis-
tinctive characteristics:
1. Highly active in international markets from or near 
inception
2. Scarce financial resources and other assets
3. Internationalized entrepreneurial management
4. Compete on differentiation strategies
5. Leverage advanced information technology
6. Strategic alliances in foreign markets
Lamontagne pointed out that many of these distinctive 
characteristics  could  apply  to  any  firm  that  wishes  to 
reach  global  markets.  However,  for  born-global  firms, 
these characteristics take on a greater importance and 
these  companies  are  likely  to  possess  most  or  all  of 
these corporate traits.
Born-Global Strategies for Business Interna-
tionalization
Born-global companies typically make use of an arsenal 
of capabilities to help overcome the challenges of being 
a  small  player  in  a  competitive  marketplace.  Well-
defined  strategic  orientation  is  critical  and  manage-
ment must adapt strategies to the specific needs of the 
firm.  Even  if  we  arrive  at  a  single  definition  of  "born 
global", it is likely that no single approach is appropri-
ate for all companies, at all times, in all markets. Yet, 
most born globals share two common success factors: i) 
resourcefulness and ii) dynamic capabilities of manage-
ment and the firm. 
A Pharmaceutical Startup Perspective
In Lamontagne's experience, he argues that practically 
all pharmaceutical startups are born global by default 
and this approach has always been a feature of this in-
dustry. This does not necessarily mean that internation-
alization within pharmaceutical companies is always by 
design, but the industry has always been an exception 
to the traditional staged model of internationalization. 
No company develops a medicine solely for a domestic 
market. By default, nearly all pharmaceutical products 
are  aimed  at  a  global  market,  and  related  financing, 
R&D, manufacturing, strategic alliances, etc. tend to be 
global.  Thus,  entrepreneurial  founders  "think  global 
from inception" in all key aspects of the business, in-
cluding  markets,  commercialization,  product  develop-
ment,  manufacturing,  intellectual  capital  (i.e., 
management, expert resources and IP) and strategic al-
liances.  Investments  in  projects  to  derive  significant 
global competitive advantages are the norm.
Lamontagne next described recent changes to business 
models  in  the  pharmaceutical  industry.  The  develop-
ment  of  medicines  used  to  be  mostly  the  domain  of 
large multinationals. However, the advent of genetic en-
gineering  in  the  1970s  allowed  entry  of  small  firms, 
which  can  now  compete  head-to-head  with  multina-
tionals. Multinationals have responded by increasingly 
focusing  on  the  revenue  side  of  the  pharmaceutical 
business,  thus  becoming  large  marketing  engines  for 
pharmaceutical  products,  many  of  which  were  de-
veloped  through  more  cost-effective  out-sourcing/alli-
ances and acquisitions with smaller firms. 
Although Lamontagne argues that pharmaceutical star-
tups are born global by default, the evolution in busi-
ness  models  underscore  several  increasingly  relevant 
elements of the born-global concept: 
1.  Understanding  market  nuances  and  demands  prior 
to product development is critical.
2.  Success  depends  on  worldwide  strategic  alliances, 
particularly for marketing.
3. Companies must comply with regulations in multiple 
jurisdictions, which greatly impacts strategies for clinic-
al trials.
4. An entrepreneurial management team that has inter-
national experience and "know-how" is essential.Technology Innovation Management Review September 2012
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5. Manufacturing typically involves multiple geographies.
6. R&D depends on worldwide strategic alliances (both 
private and public).
7. From inception, there must be a global strategy for in-
tellectual property.
8. Pharmaceutical companies must seek global sources 
of  investment  capital;  Canada  lacks  sufficient  invest-
ment capital to support the biopharmaceutical industry 
through its requirement for multiple successive finan-
cing  rounds  as  potential  products  move  through  pre-
clinical and clinical development phases.
Conclusion
In closing, Lamontagne emphasized the attractiveness 
of the born-global approach in light of the ever-increas-
ing globalization of markets. He called for support for 
born-global companies by business and financial lead-
ers,  stakeholder  communities,  academic  scholars,  and 
government  policies  and  programs.  Lamontagne  con-
cluded by saying: “From an intuitive perspective, 'born 
global'  is  a  simple  business  concept;  however,  the 
strategies and execution behind it are very complex and 
challenging. And, of course, we only hear about the suc-
cess stories - there are several questions that remain un-
answered. The jury on 'born global' is still out.”
Lessons Learned 
In  the  discussions  that  followed  the  first  and  second 
parts  of  the  presentation,  audience  members  shared 
the lessons they learned from the presentation and in-
jected  their  own  knowledge  and  experience  into  the 
conversation. 
The  audience  also  identified  the  following  key 
takeaways from the presentation:
1.  Globalization  seems  to  be  an  artefact  of  global 
change, especially the development of the Internet.
2. You can be small and global.
3.  The  chances  of  global  success  are  increased  by 
founder experience, international management experi-
ence, and networks. These factors are particularly valu-
able  when  trying  to  globalize  with  scarce  resources. 
Infrastructure can also enable success.
4. There is no specific recipe for success, nor is there a 
common definition of "born global".
5. Dynamic capabilities are essential; born-global com-
panies must be flexible.
6.  Opportunities  lie  in  niche  markets  that  are  world-
wide.
7. Thinking about going global from Day 1 is different 
from implementing from Day 1. 
8. If you wish to be a born-global company, it is essen-
tial  to  understand  your  target  market,  even  more  so 
than  for  other  companies.  This  includes  knowing  the 
costs  and  benefits  of  conducting  business  in  each  re-
gion.
9. Large companies are increasingly becoming market-
ing  machines  that  outsource  R&D.  Therefore,  small 
companies can compete, or at least co-exist, with large 
global players through niche R&D. However, for an indi-
vidual company, the risk is that all the eggs are in one 
basket. 
10. To be born global, you need to approach the prob-
lem of globalization differently. It is not about deploy-
ing a large, international sales force. Born globals need 
to rely on new strategies that leverage the help of oth-
ers, both locally and globally.Technology Innovation Management Review September 2012
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About the Speaker
Louis Lamontagne is the President and CEO of LTL 
Global  Innovations  and  Management,  Inc.,  which 
he founded in 2009. LTL Global Innovations and its 
wholly-owned  subsidiary  LTL  Global  BioEnergy 
Corp. are primarily focused on the development and 
commercialization of renewable and sustainable co-
generation of combined heat and power (CHP) mod-
ular technologies using biomass as fuel. He was re-
cently appointed as Global Practice Lead for the Life 
Sciences in Canada by the Department of Foreign Af-
fairs and International Trade (DFAIT) and is interim 
CEO  of  Alztech,  a  USA  based  biopharma  company 
focused on the development of novel therapies for 
Alzheimer’s  Disease.  Dr.  Lamontagne  formerly 
served  on  the  Board  of  Canada’s  Natural  Sciences 
and Engineering Research Council (NSERC) (and is 
a member of the Council’s Committee on Research 
Partnerships), the Board of Governors of Algonquin 
College, the Board of Directors of the Ottawa Hospit-
al  Research  Institute  (OHRI)  representing  the  Ott-
awa  Hospital,  the  Riverside  Hospital,  the  Civic 
Hospital,  the  Children’s  Hospital  for  Eastern 
Ontario,  and  the  Heart  Institute.  He  is  also  on  a 
Board of Advisors for the Canada Science and Tech-
nology  Museums  Corporation,  comprising  of  the 
Canada Food and Agriculture Museum, the Canada 
Aviation  and  Space  Museum,  and  the  Canada  Sci-
ence and Technology Museum.
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